Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

11,000 pts w exon 20 mutations who benefit (potentially) from poziotinib in NSCLC. From cancer.org there are about 225,000 pts w lung cancer and 80 to 85% are NSCLC. And from the reference info in my previous post ~3% are EGFR exon 20 insertion mutations so 225,000 * .825 * .03 = 5506 pts which matches # in the previous post. And for HER2 exon 20 mutant NSCLC it’s the same. Two posts ago, the reference indicated about 3% of NSCLC are HER2 exon 20 mutations, the same as for the EGFR side of things, so double 5500 and you get 11,000 pts who could potentially benefit from this therapy.